Loading clinical trials...
Loading clinical trials...
Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL and ≤ 2000 mg/dL
Conditions
Interventions
AMR101 (ethyl icosapentate) - 4 g/day
AMR101 (ethyl icosapentate) - 2 g/day
+1 more
Locations
60
United States
Amarin Investigational Site
Sacramento, California, United States
Amarin Investigational Site
Golden, Colorado, United States
Amarin Investigational Site
Miami, Florida, United States
Amarin Investigational Site
Miami, Florida, United States
Amarin Investigational Site
Ocala, Florida, United States
Amarin Investigational Site
Addison, Illinois, United States
Start Date
December 1, 2009
Primary Completion Date
October 1, 2010
Completion Date
July 1, 2011
Last Updated
April 25, 2022
NCT06822790
NCT06564584
NCT06992323
NCT05610280
NCT07349615
NCT07352124
Lead Sponsor
Amarin Pharma Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions